The beta adrenergic agonist isoproterenol suppress voluntary alcohol intake in rats

Roles of the locus coeruleus and adrenergic receptors in brain-mediated hypothalamic-pituitary-adrenal axis responses to intracerebroventricular alcohol

BACKGROUND

Alcohol activates the hypothalamic-pituitary-adrenal (HPA) axis through its actions in both the periphery and the central nervous system (CNS). The studies presented here were designed to test the CNS-specific noradrenergic mechanisms by which alcohol stimulates HPA activity in the male rat.

METHODS

We used an experimental paradigm in which a small, nontoxic amount (5 μl) of alcohol was slowly microinfused intracerebroventricularly (icv). Alcohol was administered icv to animals with lesions of the locus coeruleus (LC) or in animals pretreated with α- or β-adrenergic receptor antagonists. Hormonal HPA activation was determined by measuring secretion of the pituitary stress hormone adrenocorticotropin (ACTH). Neuronal activation was determined by quantification of the expression of the transcription factor c-fos (Fos).

RESULTS

As expected, icv alcohol stimulated ACTH secretion from the pituitary and Fos expression in the paraventricular nucleus of the hypothalamus (PVN). Bilateral electrolytic LC lesions blocked the ability of icv alcohol to stimulate ACTH secretion. Pretreatment with icv propranolol increased basal ACTH secretion levels, but icv alcohol did not increase this effect. Propranolol also blunted icv alcohol-induced PVN Fos expression. A low dose of phenoxybenzamine, an α-adrenergic receptor antagonist, did not affect the ability of icv alcohol to stimulate ACTH release. However, a higher dose of the drug was able to block the ACTH response to icv alcohol. Despite this, phenoxybenzamine did not inhibit alcohol-induced Fos expression. Icv pretreatment with corynanthine, a selective α-1 adrenergic receptor antagonist, modestly raised basal ACTH levels and blocked the icv alcohol-induced secretion of this hormone.

CONCLUSIONS

These results indicate that the LC and norepinephrine play important roles in HPA activation caused by icv alcohol administration, but that the specific adrenergic receptor subtypes involved in this phenomenon still need to be identified.

There and back again: a tale of norepinephrine and drug addiction

Fueled by anatomical, electrophysiological, and pharmacological analyses of endogenous brain reward systems, norepinephrine (NE) was identified as a key mediator of both natural and drug-induced reward in the late 1960s and early 1970s. However, reward experiments from the mid-1970s that could distinguish between the noradrenergic and dopaminergic systems resulted in the prevailing view that dopamine (DA) was the primary 'reward transmitter' (a belief holding some sway still today), thereby pushing NE into the background. Most damaging to the NE hypothesis of reward were studies demonstrating that NE receptor antagonists and NE reuptake inhibitors failed to impact drug self-administration. In recent years new tools, such as genetically engineered mice, and new experimental paradigms, such as reinstatement of drug seeking following withdrawal, have propelled NE back into the awareness of addiction researchers. Of particular interest is disulfiram, an inhibitor of the NE biosynthetic enzyme dopamine beta-hydroxylase, which has demonstrated promising efficacy in the treatment of cocaine dependence in preliminary clinical trials. The purpose of this review is to synthesize the new data linking NE to critical aspects of DA signaling and drug addiction, with a focus on psychostimulants (eg, cocaine), opiates (eg, morphine), and alcohol.

Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats

We have recently shown that tyrosine-hydroxylase immunostaining (TH-IM) is selectively decreased in the cingulate cortex and in the shell of the nucleus accumbens (nAcc) of Sardinian alcohol-preferring rats (sP) when compared with Sardinian alcohol-non preferring (sNP) and Wistar (W) rats. Since these regions contain both dopamine and noradrenaline (NA) fibers, clarification of the dopaminergic and noradrenergic contribution to the decreased TH-immunoreactivity was needed. To this aim, we carried out the present immunohistochemistry study using two antibodies raised against dopamine beta-hydroxylase (DBH), the enzyme responsible for the conversion of dopamine into noradrenaline, and against the dopamine transporter (DAT), as markers for noradrenergic and dopaminergic fibers, respectively. The results show that DBH-immunostaining (DBH-IM) and DAT-immunostaining (DAT-IM) were both lower in the cingulate cortex of the sP rats with respect to sNP and W rats. In the shell of the nAcc a reduced DAT-IM in sP rats was found, while the DBH-IM did not differ between the three lines of rats. The analysis of the cell-body area of noradrenergic neurons in the locus coeruleus, revealed no differences between sP, sNP and W rats. These results indicate a selective reduction of the terminal innervation in the mesocorticolimbic dopamine and NA systems in sP rats. This genetically-determined difference may be involved in the opposite alcohol preference and consumption of sP and sNP rats.

Ethanol-associated behaviors of mice lacking norepinephrine

Although norepinephrine (NE) has been implicated in animal models of ethanol consumption for many years, the exact nature of its influence is not clear. Lesioning and pharmacological studies examining the role of NE in ethanol consumption have yielded conflicting results. We took a genetic approach to determine the effect of NE depletion on ethanol-mediated behaviors by using dopamine beta-hydroxylase knockout (Dbh -/-) mice that specifically lack the ability to synthesize NE. Dbh -/- males have reduced ethanol preference in a two-bottle choice paradigm and show a delay in extinguishing an ethanol-conditioned taste aversion, suggesting that they drink less ethanol in part because they find its effects more aversive. Both male and female Dbh -/- mice are hypersensitive to the sedative and hypothermic effects of systemic ethanol administration, and the sedation phenotype can be rescued pharmacologically by acute replacement of central NE. Neither the decreased body temperature nor changes in ethanol metabolism can explain the differences in consumption and sedation. These results demonstrate a significant role for NE in modulating ethanol-related behaviors and physiological responses.

Acetaldehyde inhibits serum aminopeptidases

Aminopeptidase A (APA)- and aminopeptidase M (APM)-like activity were assayed in Moni-Trol ES with L-alpha-aspartyl-beta-naphthylamide and L-alanyl-beta-naphthylamide, respectively. Upon preincubation of the serum with 89.4, 223.5, and 447 mM acetaldehyde at room temperature for 30 min, a reduction in 26.8%, 55.3%, and 75.8% aminopeptidase A activity was observed. Similarly, aminopeptidase M activity was reduced by 26.5% and 53.1% upon preincubation with 223.5 and 447 mM acetaldehyde. Ethanol at 84.9, 212.3, and 427.9 mM did not significantly affect the enzymic activity. Because aminopeptidase A and aminopeptidase M also degrade the pressor substance, angiotensin II, it is suggested that inhibition of aminopeptidase A- and aminopeptidase M-like activity by acetaldehyde, the product of ethanol metabolism, may lead to higher levels of circulating angiotensin II and, consequently, hypertension, in alcoholics. The hydrolysis of lysine-p-nitroanilide, an aminopeptidase B substrate, was also inhibited upon addition of acetaldehyde to Moni-Trol ES serum.

The benzodiazepine antagonist CGS 8216 prevents hyperammonemia-induced somatostatin receptor reduction in the brain

Previous results from our group showed that hyperammonemia decreases the number of somatostatin (SS) receptors and that benzodiazepine receptors might regulate the number of SS receptors in rat brain. These findings together with the supersensitivity of benzodiazepine receptors in the hyperammonemic rat brain suggest that benzodiazepine receptors might mediate the effect of hyperammonemia on SS receptors. To assess this hypothesis we tested whether 2-phenylpyrazolo[3,4-c]-quinolin-3(5H)-one (CGS 8216), a benzodiazepine antagonist, prevented the effect of ammonium acetate on rat brain SS receptors. Administration of ammonium acetate (5 mmol/kg, i.p.) for 7 days did not affect the levels of somatostatin-like immunoreactivity but decreased the number of SS receptors in synaptosomes from the frontoparietal cortex and hippocampus without affecting their apparent affinity. This decrease could be blocked by the concomitant administration of CGS 8216 (10 mg/kg, i.p.). The benzodiazepine antagonist alone had no observable effect on the somatostatinergic system. These results suggested that the effect of hyperammonemia on SS receptors could be mediated, at least in part, through the benzodiazepine receptors.

Increased alcohol consumption in weight-reduced rats is modulated by the renin-angiotensin system

Weight reduction and food restriction increase the self-administration of alcohol and other drugs of abuse, but the underlying physiological mechanisms have not been identified. Because weight reduction alters angiotensin (ANG) II activity, and ANG II is known to modulate alcohol intake, ANG II may play a role in the enhanced alcohol consumption of food-deprived weight-reduced rats and in the drop in alcohol intake when these rats are refed. Two groups of rats were reduced to and maintained at 80% of their free feeding weights and offered daily 40 min access to a 6% (w/v) alcohol solution and water. Water was available ad lib. After alcohol intake stabilized, one group was given daily injections of the angiotensin converting enzyme inhibitor captopril (5.0 mg/kg) for 6 days while the other group received the saline vehicle. Following this, each group continued to receive either captopril or vehicle injections but was returned to ad lib feeding. Captopril did not alter alcohol intake when the rats were food-deprived and weight-reduced, but did significantly attenuate the decline in alcohol consumption compared to the vehicle group when both groups were refed and regaining weight. These findings suggest that the increase in alcohol intake with food restriction and its decline following refeeding are, in part, related to changes in ANG II activity.

Dietary salt and voluntary ethanol consumption in golden hamsters

Adult male golden hamsters were maintained on powdered Purina chow and tap water, and were permitted continuous access to either a 15% or a 30% ethanol solution (v/v); after an initial 4-5 weeks of ethanol availability, hamsters had stabilized their intakes and were deriving an average of 1.25 and 1.96 g/day of absolute ethanol from the 15% and 30% solutions, respectively. When salt was added to the diet in increasing concentrations ranging from 4% to 10% over a period of 40 days, hamsters reduced chow-derived calories by up to 35%, increased tap water consumption by up to 50%, and increased consumption of ethanol solutions by up to 100%; when unadulterated Purina chow was reinstated, intakes of chow-derived calories, tap water, and ethanol solutions returned to baseline levels. Hamsters that were continuously maintained on unadulterated Purina chow, but with chow-derived calories matched to that of animals on the salt-adulterated diet, significantly increased their ethanol intake, but not their tap water intake; the increase in their ethanol intake was only about half as large as that of hamsters that had salt added to the diet, but the increase persisted even after ad lib feeding was reinstated. The results indicate that the addition of salt to the diet of hamsters produces large increases in ethanol consumption; furthermore, the increased ethanol intake is not simply the result either of a nonselective increase in fluid consumption or of the reduction in food intake that accompanies the addition of salt to the diet. Results are related to the possible role of the renin-angiotensin system in the control of ethanol consumption in the golden hamster.

New drugs for the treatment of experimental alcoholism

This article presents a current overview of the efforts to suppress pharmacologically the craving, dependence, or other factors associated with the self-selection of alcohol in an experimental animal. The contemporary status of the pharmacotherapy of experimental alcoholism similarly is described for different animal models of alcohol drinking. An evaluation is presented of several classes of drug for their efficacy in ameliorating the volitional ingestion of alcohol in the presence of an alternative fluid. Currently, two main experimental animal models of alcoholism are being used in this endeavor: (a) genetic lines or substrains of high alcohol preferring or high drinking rats; and (b) strains of nondrinking or low alcohol preferring rats which are induced chemically to prefer alcohol. Because of technical, methodological, and other issues surrounding the procedures used to assess the efficacy of a drug in reducing alcohol intake, several of the newer findings remain controversial. For example, serious side effects on the intake of food, caloric regulation, motor activity, or other functions would preclude the clinical utility of the drug. However, several drugs which affect monoaminergic neurons as well as opioid systems in the brain now seem to offer promise as agents which do possess clinical benefits. Two of these drugs, FG5606 (amperozide) and FG 5893 are essentially "antialcoholic" or anticraving and are without any significant side effects on cerebral mechanisms responsible for hunger, caloric intake, motor activity, or other physiological process. Amperozide, a 5-HT2 receptor antagonist with dopamine releasing properties, is particularly notable because of its irreversible nature in attenuating alcohol preference for months after its administration. It is concluded that future pharmacological research on presently available and newly developed compounds will provide exciting opportunities to the clinician who can utilize a particular drug as an adjunctive tool in the therapeutic treatment of the alcoholic individual.

The reduction in alcohol intake produced by enalapril is not attenuated by centrally administered angiotensin inhibitors

Angiotensin-converting enzyme (ACE) inhibitors, which prevent the conversion of angiotensin I to angiotensin II, reduce alcohol intake when injected peripherally. The mechanism by which ACE inhibitors produce this effect on alcohol intake is unknown. A rise in the biosynthesis of angiotensin II in the periphery is known to reduce alcohol intake. In this experiment, we examine the possibility that the reduction in alcohol intake produced by an ACE inhibitor, enalapril, is mediated by a rise in angiotensin II in the brain. Enalapril, 20 mg/kg, injected intraperitoneally, produced a 40% reduction in alcohol intake. This reduction was not attenuated by the concurrent administration into the lateral ventricle of either the ACE inhibitors captopril or ceranapril (1, 10, or 25 micrograms), or the angiotensin II receptor antagonist Sar1-Thr8-Angiotensin II (5 micrograms). These findings suggest that the ACE inhibitors do not reduce alcohol intake by raising angiotensin II in the brain.

Captopril and hydrochlorothiazide (Capozide) combine to enhance the reduction in voluntary alcohol intake in rats

The effect of Capozide, the combination of captopril with a hydrochlorothiazide diuretic, on voluntary alcohol intake was assessed in two experiments. In experiment 1 naive rats who were maintained on ad libitum food and water were given daily 40-min access to a 6% (w/v) alcohol solution and water. Daily intraperitoneal injections of captopril (10 mg/kg) reduced alcohol intake, but the combination of captopril (5 and 10 mg/kg) and hydrochlorothiazide (2.5, 5, and 10 mg/kg) enhanced the reduction in intake. In experiment 2, captopril alone, hydrochlorothiazide alone, and the combination of captopril and hydrochlorothiazide were again administered daily in the limited access procedure. Captopril (10 mg/kg) again reduced alcohol intake as did all three doses of hydrochlorothiazide (2.5, 5, and 10 mg/kg). Compared with the individual effects of captopril and hydrochlorothiazide, Capozide exerted a supra-additive reduction in alcohol intake. These effects were not due to drug-induced changes in the pharmacokinetics of alcohol. Taken together these results demonstrate an enhanced potency of Capozide in suppressing alcohol intake and invite their testing in a population of hypertensive alcoholics and alcohol abusers.

Reduction of ethanol intake by aerosol inhalation of a beta-adrenergic agonist: new route--new treatment approach?

The quick, convenient, unobtrusive administration of a low dose of a drug that effectively reduces alcohol intake could be a useful adjunct to any program that aims to treat alcohol abuse. This study evaluates the ability of isoproterenol, a drug that has previously been shown to reduce ethanol intake, to exercise this action when administered as a metered aerosol mist. Rats were trained to self-administer ethanol using a procedure that limits access to a brief daily availability period. Once intake stabilized, animals were given isoproterenol by metered aerosol inhalation just before ethanol availability. A custom-designed helmet attached to a commercially available mistometer was used to deliver the drug. Isoproterenol produced a dose-dependent reduction in ethanol intake and an increase in water intake replicating the effects of parenterally administered isoproterenol on ethanol and water consumption. These findings demonstrate that the administration of isoproterenol in inhaled aerosol form can effectively reduce voluntary ethanol consumption in rats. The administration of pharmacologically active antialcohol agents via the inhalation route may be useful in the symptomatic treatment of alcohol abuse in humans.

Effect of ammonium acetate on the somatostatinergic system in the rat frontoparietal cortex

Short (90 min)-, mid (5 days)-, and long-term (15 days) ammonium acetate (5 mmol/kg IP) administration decreased the number of specific [125I][Tyr11]somatostatin receptors in synaptosomes from the frontoparietal cortex without changing the affinity constant. Administration of ammonium acetate did no affect the levels of somatostatin-like immunoreactivity in the frontoparietal cortex. The administration of a single dose of N-carbamyl-L-glutamate (1 mmol/kg) plus L-arginine (1 mmol/kg) 1 h before the last administration of ammonium acetate totally blocked the inhibitory effects of the latter on somatostatin receptor number in the frontoparietal cortex synaptosomes. N-Carbamyl-L-glutamate plus L-arginine alone had no observable effect on the somatostatinergic system. The decrease in the number of somatostatin receptors induced by ammonium acetate might reflect decreased target cell sensitivity to somatostatin, a phenomenon that could contribute to the depressed neuronal excitability induced by ammonia in the rat frontoparietal cortex.

Angiotensin and captopril increase alcohol intake

Reportedly both angiotensin II (ANG II) and angiotensin-converting enzyme (ACE) inhibitors reduce ethanol intake when they are injected SC into certain chronic experimental conditions in the rat. The ACE inhibitors are suggested to reduce ethanol intake by increasing ANG II synthesis in the brain. The present results show that several different methods can produce opposite effects of ANG II and the ACE inhibitor captopril on ethanol intake. Continuous intraventricular infusions of ANG II for 7 days or low doses of oral or SC-infused captopril for up to 12 days increased the intake of ethanol. The only reduction of ethanol intake resulted from a universal blockade of all ACE in both the brain and periphery, a condition in which ANG II could not possibly mediate the decrease. The results contradict the hypothesis that ethanol intake is suppressed by centrally acting or centrally synthesized ANG II. ACE inhibitors may reduce ethanol intake only when they affect the brain as well as the periphery.

The amino acid composition of angiotensin alters its ability to reduce alcohol consumption in rats

The voluntary consumption of alcohol has been shown to be reduced by a variety of manipulations which enhance activity in the renin-angiotensin system, including the administration of the bovine form of angiotensin II-[Val5]-ANG II. The present study investigated the relationship between the amino acid composition of angiotensin II and its ability to reduce alcohol intake by administering a number of different forms or fragments of the parent peptide. [Ile5]-Angiotensin II ([Ile5]-ANG II), two endogenous fragments of angiotensin II [( Des-Asp1]-ANG II and [Des-Phe8]-ANG II) were administered subcutaneously in rats across a range of doses. [Ile5]-ANG II reduced alcohol intake at all doses tested between 20 and 400 micrograms/kg while [Des-Asp1]-ANG II reduced alcohol intake only at the 400 micrograms/kg dose. [Des-Phe8]-ANG II had no effect on alcohol intake at any dose tested. Administration of the antagonist [Sar1-Thr8]-ANG II by itself did not enhance alcohol intake. While the pressor and dipsogenic properties of these fragments sometimes correlated with the reduction in alcohol intake they were not a causal factor in decreasing the intake. These results indicate that variations in the peptide composition of angiotensin can significantly alter its ability to reduce the consumption of alcohol.

Regulation of alcohol consumption by the renin-angiotensin system: a review of recent findings and a possible mechanism of action

The renin-angiotensin system has traditionally been associated with the regulation of fluid and electrolyte balance. In this review we summarize the data which ascribes a completely new function to this system, i.e., the regulation of alcohol consumption. In addition, we suggest a possible mechanism for this effect based on the concept of a satiety or stop process. The approach taken was to examine the effect on alcohol intake of a wide variety of drug, genetic, dietary, surgical and neurosurgical manipulations, each of which has a range of biological effects characteristic of that manipulation, but all of which share the common property of altering activity in the renin-angiotensin system. The effect of these manipulations on alcohol intake was most parsimoniously explained by reference to their ability to raise or lower activity in the renin-angiotensin system. Any intervention which modulates activity in this system, either directly or indirectly, is likely to have consequences for alcohol consumption.

The influence of the renin gene on alcohol consumption in Dahl rats

A rat renin allele (the S-allele) has been identified in Dahl rats which cosegregates with increases in blood pressure. Rats with a double dose of the allele--the salt-sensitive hypertensive rats--have low renin activity compared with the salt-resistant hypertensive rat that does not have this S-allele. Alcohol consumption in rats has also been shown to vary with renin activity, and the possible involvement of renin activity in the genetics of alcohol consumption was suggested by previous work showing that the alcohol-preferring P line of selected rats had low renin levels. In the present study we examined alcohol consumption in a group of inbred Dahl rats, which have a double dose of the S renin allele, and in a group of selected Dahl rats, which have only a single dose of this S-allele. After an initial acclimation period, these two groups were first given daily 1-hr access to ascending concentrations of alcohol (3%, 6%, 8% w/v) over a 34-day period followed by continuous access to alcohol for a further 10 days. Water and food were always available. Regardless of whether alcohol was rationed or continuously available, the rats with the double dose of the S-allele drank significantly more alcohol than the rats that had only a single dose of this allele. These findings suggest that genetically mediated alterations in the renin gene may exert a significant influence on alcohol consumption and may be a component in the etiology of alcoholism.

Vasopressin does not mediate the inhibition of ethanol drinking by the renin-angiotensin system

Manipulations which are known to enhance activity in the renin-angiotensin system (RAS) have been found to reduce the voluntary consumption of ethanol in rats. Since angiotensin II is a potent stimulus for the release of vasopressin (VP), it is possible that the RAS modulates ethanol (ETOH) consumption through a mechanism involving VP. The present investigation examined the effect of peripheral injections of arginine-VP (AVP) and desglycinamide-AVP (DGAVP) on ETOH consumption in rats given daily one-hour access to ETOH. Daily subcutaneous treatment with AVP or DGAVP had no effect on ETOH consumption at doses ranging from 2 to 200 micrograms/kg (SC). Blood pressure was substantially elevated following a single 20 microgram/kg injection of AVP, indicating that AVP was biologically active at doses which failed to alter ethanol consumption. These findings indicate the VP does not affect established ETOH drinking and furthermore is not likely a critical factor in the reduction of ETOH intake by the RAS.

Angiotensin converting enzyme inhibitors reduce alcohol consumption: some possible mechanisms and important conditions for its therapeutic use

Alcoholism is a prevalent problem of contemporary society, yet there are virtually no clinically effective drugs for the management of this disorder. A previous study demonstrating the ability of angiotensin-converting enzyme (ACE) inhibitors to attenuate voluntary alcohol intake in rats prompted the suggestion that these drugs, currently marketed for the treatment of hypertension, may also be useful in dealing with human alcohol abuse. The present experiments explored in more detail the effect and possible mechanisms of action of this class of drug on alcohol consumption in rats. Experiment one demonstrated that Abutapril, a new ACE inhibitor, significantly reduced alcohol intake and that this effect could not be blocked by either an ANG II or an opiate receptor antagonist suggesting that neither the peripheral renin-angiotensin system (RAS) nor the endogenous enkephalins are involved in the ability of ACE inhibition to attenuate alcohol intake. Experiments two and three showed that ACE inhibition effectively reduced alcohol drinking faster in animals with elevated RAS activity and not at all in animals with suppressed RAS activity indicating that initial levels of RAS activity may determine the speed and ability of ACE inhibition to attenuate alcohol intake. ACE inhibitors may reduce alcohol intake by elevating a nonapeptide fragment or by elevating central ANG II levels. The assessment of this class of drugs to reduce alcohol intake in humans should include a monitoring of the initial level of activity in the renin-angiotensin system since this may be a predictor of the effectiveness of treatment with the ACE inhibitors.